Phase 3 trial of Mevrometostat, an EZH2 inhibitor, with Enzalutamide in metastatic castration-sensitive prostate cancer

This randomized trial evaluates whether combining investigational Mevrometostat with enzalutamide improves outcomes for ARPI-naïve, chemo-naïve metastatic castration-sensitive prostate cancer patients compared to enzalutamide alone. Sponsored by Pfizer, the study examines a novel approach integrating an EZH2 inhibitor with an established androgen receptor blocker.